BR0310042A - Vacinas de combinação mucosal para meningite bacteriana - Google Patents

Vacinas de combinação mucosal para meningite bacteriana

Info

Publication number
BR0310042A
BR0310042A BR0310042-1A BR0310042A BR0310042A BR 0310042 A BR0310042 A BR 0310042A BR 0310042 A BR0310042 A BR 0310042A BR 0310042 A BR0310042 A BR 0310042A
Authority
BR
Brazil
Prior art keywords
bacterial meningitis
mucosal
induces
antigen
immune response
Prior art date
Application number
BR0310042-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Derek Thomas O'hagan
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BR0310042A publication Critical patent/BR0310042A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR0310042-1A 2002-05-14 2003-05-14 Vacinas de combinação mucosal para meningite bacteriana BR0310042A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38067502P 2002-05-14 2002-05-14
PCT/IB2003/002648 WO2003094960A2 (en) 2002-05-14 2003-05-14 Mucosal combination vaccines for bacterial meningitis

Publications (1)

Publication Number Publication Date
BR0310042A true BR0310042A (pt) 2005-04-05

Family

ID=29420626

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0310042-1A BR0310042A (pt) 2002-05-14 2003-05-14 Vacinas de combinação mucosal para meningite bacteriana

Country Status (12)

Country Link
US (2) US20060147466A1 (cg-RX-API-DMAC7.html)
EP (1) EP1506007B1 (cg-RX-API-DMAC7.html)
JP (2) JP4662537B2 (cg-RX-API-DMAC7.html)
CN (2) CN1816350B (cg-RX-API-DMAC7.html)
AT (1) ATE513560T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003239744B2 (cg-RX-API-DMAC7.html)
BR (1) BR0310042A (cg-RX-API-DMAC7.html)
CA (1) CA2485999C (cg-RX-API-DMAC7.html)
MX (1) MXPA04011248A (cg-RX-API-DMAC7.html)
NZ (1) NZ536859A (cg-RX-API-DMAC7.html)
RU (1) RU2378008C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003094960A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
AU2011224064A1 (en) * 2003-10-02 2011-10-06 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
EP2269638A3 (en) * 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008101349A1 (en) 2007-02-23 2008-08-28 Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence Recombinant viral vectors for prevention and protection against alphavirus infection
CN101249261B (zh) * 2008-03-18 2010-10-27 中国疾病预防控制中心病毒病预防控制所 一种肾综合征出血热粘膜免疫疫苗及其制备方法
EP2440251A4 (en) * 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN104383531A (zh) * 2014-11-18 2015-03-04 北京智飞绿竹生物制药有限公司 预防儿童脑膜炎的联合疫苗及其制备方法
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN105031644A (zh) * 2015-06-25 2015-11-11 中国科学院过程工程研究所 一种疫苗佐剂及含该疫苗佐剂的疫苗组合物和疫苗制剂
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION AND USES THEREOF
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
CN113164580B (zh) 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗
RU2704452C1 (ru) * 2019-04-22 2019-10-28 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства Способ получения вакцины гемофильной тип b конъюгированной
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3185429A1 (en) * 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Bacterial immunization using nanoparticle vaccine
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
RO111416B1 (ro) * 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0994723A1 (en) * 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DE69939943D1 (de) * 1998-10-21 2009-01-02 Kitasato Inst Attenuierte Toxine als Adjuvantien
CA2366152A1 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
JP3980884B2 (ja) * 2000-02-15 2007-09-26 アイディー バイオメディカル コーポレイション オブ ケベック プロテオソーム・インフルエンザ・ワクチン
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ES2399386T3 (es) * 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ES2339762T3 (es) * 2002-01-14 2010-05-25 Novartis Vaccines And Diagnostics, Inc. Vacuna contra el vih y procedimiento de uso.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery

Also Published As

Publication number Publication date
WO2003094960A3 (en) 2004-03-04
MXPA04011248A (es) 2005-02-17
US20060147466A1 (en) 2006-07-06
CA2485999C (en) 2015-02-17
CN1816350A (zh) 2006-08-09
US20110159030A1 (en) 2011-06-30
CA2485999A1 (en) 2003-11-20
AU2003239744A1 (en) 2003-11-11
AU2003239744B2 (en) 2008-07-03
RU2004136295A (ru) 2006-03-20
JP2010202672A (ja) 2010-09-16
EP1506007A2 (en) 2005-02-16
CN1816350B (zh) 2010-11-10
EP1506007B1 (en) 2011-06-22
JP4662537B2 (ja) 2011-03-30
NZ536859A (en) 2007-11-30
ATE513560T1 (de) 2011-07-15
CN1684707A (zh) 2005-10-19
JP2005526847A (ja) 2005-09-08
CN1684707B (zh) 2012-09-05
WO2003094960A2 (en) 2003-11-20
RU2378008C2 (ru) 2010-01-10

Similar Documents

Publication Publication Date Title
WO2003094960A3 (en) Mucosal combination vaccines for bacterial meningitis
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
MY125202A (en) Vaccine
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
NZ562998A (en) Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
BRPI0407101A (pt) Vacinas meningocócicas mucosais
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
MX348734B (es) Vacunacion multiple que incluye meningococcus del serogrupo c.
WO2006081259A3 (en) Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
WO2005027829A3 (en) Method for vaccination of poultry by bacteriophage lysate
AP2004003074A0 (en) Adjuvanted antigenic meningococcal compositions
SG147465A1 (en) Vaccine
DE60333027D1 (de) Antigene zusammensetzungen zur immunisierung nichtmenschlicher säuger gegen streptococcus equi
GB2444676A (en) Adjuvanted vaccine
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
ATE495757T1 (de) Attenuierte bakterielle lebendvakzine
WO2004043286A3 (en) Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
IL164242A (en) Vaccine containing streptococcus pneumoniae proteins associated with age-dependent immune response

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. (IT)

Free format text: ALTERADO DE: CHIRON S.R.L.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]